biopharmaceutical company Regeneron Pharmaceuticals, Inc. (REGN) posted a net profit for the fourth quarter of $470 million or $4.08 per share, compared to a net loss of $53 million or $0.58 per share in the year-ago quarter.
On a non-GAAP basis, profit was $171 million or $1.47 per share. On average, 15 analysts polled by Thomson Reuters expected the company to report earnings per share of $1.11 for the quarter. Analysts' estimates typically exclude one-time items.
For the quarter, the Company's total revenues surged to $415 million from $123 million in the last year. Total revenues included EYLEA U.S. net product sales of $276 million and collaboration revenues of $127 million in the fourth quarter
For 2013, the company said it expects continued strong U.S. growth for EYLEA and forecast U.S. net sales of $1.2 billion - $1.3 billion.
For comments and feedback: editorial@rttnews.com